Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis by Françoise Rothé, David Venet, Dieter Peeters, Ghizlane Rouas, Mattia Rediti, Dominiek Smeets, Floriane Dupont, Peter Campbell, Diether Lambrechts, Luc Dirix, Christos Sotiriou, Michail Ignatiadis

Get full text

Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial by Mattia Rediti, David Venet, Andrea Joaquin Garcia, Marion Maetens, Delphine Vincent, Samira Majjaj, Sarra El-Abed, Serena Di Cosimo, Takayuki Ueno, Miguel Izquierdo, Martine Piccart, Lajos Pusztai, Sherene Loi, Roberto Salgado, Giuseppe Viale, Françoise Rothé, Christos Sotiriou

Get full text

Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications by Xiaoxiao Wang, David Venet, Frédéric Lifrange, Denis Larsimont, Mattia Rediti, Linnea Stenbeck, Floriane Dupont, Ghizlane Rouas, Andrea Joaquin Garcia, Ligia Craciun, Laurence Buisseret, Michail Ignatiadis, Marcela Carausu, Nayanika Bhalla, Yuvarani Masarapu, Eva Gracia Villacampa, Lovisa Franzén, Sami Saarenpää, Linda Kvastad, Kim Thrane, Joakim Lundeberg, Françoise Rothé, Christos Sotiriou

Get full text

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials by Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, Jordan D. Campbell, Karla V. Ballman, David W. Hillman, Eric P. Winer, Sarra El-Abed, Martine Piccart, Serena Di Cosimo, William Fraser Symmans, Ian E. Krop, Roberto Salgado, Sherene Loi, Lajos Pusztai, Charles M. Perou, Lisa A. Carey, Christos Sotiriou

Get full text